Meinian Onehealth Healthcare Holdings (SZSE:002044) Shareholders Have Endured a 57% Loss From Investing in the Stock Five Years Ago
Meinian Onehealth Healthcare Holdings (SZSE:002044) Shareholders Have Endured a 57% Loss From Investing in the Stock Five Years Ago
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. Zooming in on an example, the Meinian Onehealth Healthcare Holdings Co., Ltd. (SZSE:002044) share price dropped 57% in the last half decade. We certainly feel for shareholders who bought near the top.
我們認爲明智的長期投資是必經之路。但不幸的是,有些公司根本沒有成功。舉個例子,美年Onehealth醫療控股有限公司(SZSE:002044)的股價在過去五年中下跌了57%。對於那些買入接近頂部的股東,我們當然有同感。
Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.
由於從長遠來看,股東會下跌,讓我們來看看那段時間的潛在基本面,看看它們與回報是否一致。
View our latest analysis for Meinian Onehealth Healthcare Holdings
查看我們對美年康健醫療控股的最新分析
We don't think that Meinian Onehealth Healthcare Holdings' modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.
我們認爲,美尼安Onehealth Healthcare Holdings過去十二個月的微薄利潤目前並未引起市場的充分關注。我們認爲收入可能是更好的指南。一般而言,我們認爲這種公司更能與虧損股票相提並論,因爲實際利潤太低了。爲了讓股東有信心公司大幅增加利潤,它必須增加收入。
In the last half decade, Meinian Onehealth Healthcare Holdings saw its revenue increase by 3.7% per year. That's not a very high growth rate considering it doesn't make profits. It's likely this weak growth has contributed to an annualised return of 9% for the last five years. We want to see an acceleration of revenue growth (or profits) before showing much interest in this one. However, it's possible too many in the market will ignore it, and there may be an opportunity if it starts to recover down the track.
在過去的五年中,美年Onehealth Healthcare Holdings的收入每年增長3.7%。考慮到它不賺錢,這並不是一個很高的增長率。在過去五年中,這種疲軟的增長很可能導致年化回報率爲9%。在對此表現出濃厚興趣之前,我們希望看到收入(或利潤)的加速。但是,市場上可能有太多人會忽視它,如果它開始走上正軌,可能會有機會。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下圖描述了收入和收入隨時間推移而發生的變化(點擊圖片即可顯示確切的數值)。
We know that Meinian Onehealth Healthcare Holdings has improved its bottom line lately, but what does the future have in store? You can see what analysts are predicting for Meinian Onehealth Healthcare Holdings in this interactive graph of future profit estimates.
我們知道美年Onehealth Healthcare Holdings最近提高了利潤,但是未來會發生什麼?在這張未來利潤估計的交互式圖表中,你可以看到分析師對美年Onehealth Healthcare Holdings的預測。
A Different Perspective
不同的視角
We're pleased to report that Meinian Onehealth Healthcare Holdings shareholders have received a total shareholder return of 3.7% over one year. Of course, that includes the dividend. Notably the five-year annualised TSR loss of 9% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. It's always interesting to track share price performance over the longer term. But to understand Meinian Onehealth Healthcare Holdings better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Meinian Onehealth Healthcare Holdings .
我們很高興地向大家報告,美年Onehealth Healthcare Holdings的股東在一年內獲得了3.7%的股東總回報率。當然,這包括分紅。值得注意的是,五年期年化股東總回報率每年虧損9%,與最近的股價表現相比非常不利。我們通常更看重短期內的長期業績,但最近的改善可能暗示業務將出現(積極的)轉折點。長期跟蹤股價表現總是很有意思的。但是,爲了更好地了解美年Onehealth Healthcare Holdings,我們需要考慮許多其他因素。爲此,你應該注意我們在Meinian Onehealth Healthcare Holdings發現的1個警告信號。
We will like Meinian Onehealth Healthcare Holdings better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我們看到一些大規模的內幕收購,我們會更喜歡美年Onehealth Healthcare Holdings。在我們等待的同時,請查看這份免費名單,列出了最近有大量內幕買入的成長型公司。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。